Haitian Creole
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
10 rezilta yo
Monoclonal antibodies that neutralize anthrax toxins
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION
This invention relates generally to the field of immunology and specifically to monoclonal antibodies that bind and/or neutralize anthrax lethal factor (LF) or edema factor (EF).
REFERENCE TO SEQUENCE LISTING, TABLE, OR COMPUTER PROGRAM LISTING
The present application is being
Monoclonal antibodies that neutralize anthrax toxins
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION
This invention relates generally to the field of immunology and specifically to monoclonal antibodies that bind and/or neutralize anthrax lethal factor (LF) or edema factor (EF).
REFERENCE TO SEQUENCE LISTING, TABLE, OR COMPUTER PROGRAM LISTING
The present application is being
Monoclonal antibodies that neutralize anthrax toxins
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION
This invention relates generally to the field of immunology and specifically to monoclonal antibodies that bind and/or neutralize anthrax lethal factor (LF) or edema factor (EF).
REFERENCE TO SEQUENCE LISTING, TABLE, OR COMPUTER PROGRAM LISTING
The present application is being
Monoclonal antibodies that neutralize anthrax toxins
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
REFERENCE TO SEQUENCE LISTING
This application contains a Sequence Listing submitted as an electronic text file named "NIH352.sub.--001VPC_SEQ_LISTING.TXT", having a size in bytes of 98 KB, and created on Aug. 24, 2009. The information contained in this electronic file is hereby incorporated by
Monoclonal antibodies that neutralize anthrax toxins
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION
This invention relates generally to the field of immunology and specifically to monoclonal antibodies that bind and/or neutralize anthrax lethal factor (LF) or edema factor (EF).
REFERENCE TO SEQUENCE LISTING
This application contains a Sequence Listing submitted as an
Targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION
The present invention relates generally to the fields of bacteriology, immunology, and vaccine technology.
The present invention also relates to Bacillus anthracis proteins as novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure
Anthrax compositions and methods of use and production
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
TECHNICAL FIELD
The present invention relates to the field of immunology and more particularly relates to methods and compositions for treating, preventing or reducing anthrax infection in humans or animals.
BACKGROUND OF THE INVENTION
Anthrax is a disease caused by the sporulating bacteria Bacillus
Process for the preparation of non-toxic anthrax vaccine
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION
This invention relates to a Recombinant DNA construct and a process for the preparation of a nontoxic anthrax vaccine.
BACKGROUND OF THE INVENTION
Anthrax, a zoonotic disease is caused by gram-positive, sporulating bacteria, Bacillus anthracis. Humans are accidental hosts
Methods and compositions relating to anthrax pathogenesis
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION
The present invention generally relates to crystalline Edema Factor (EF) without substrate, crystalline Edema Factor-calmodulin complex without substrate and the structures of Edema Factor without substrate and Edema Factor-calmodulin complex as determined by x-ray
Rapid immunoassay of anthrax protective antigen in vaccine cultures and bodily fluids by fluorescence polarization
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION
The inventive subject matter relates to a competitive fluorescence method for estimating the concentration in a sample of Bacillus anthracis protein or specific antibody. The method contemplates the use of FLT, FRET or FP.
BACKGROUND OF INVENTION
Oral fluids have been
Baz done ki pi konplè remèd fèy medsin te apiye nan syans
- Travay nan 55 lang
- Geri èrbal te apiye nan syans
- Remèd fèy rekonesans pa imaj
- Kat entèaktif GPS - tag zèb sou kote (vini byento)
- Li piblikasyon syantifik ki gen rapò ak rechèch ou an
- Search remèd fèy medsin pa efè yo
- Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive
Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye
